source
- Sionna’s Phase 2a CF trial fails, shares plunge as Vertex’s Trikafta remains standard of careSionna Therapeutics announced that its Phase 2a cystic fibrosis trial of the NBD1 stabilizer SION-719 did not meet its primary endpoint, sending the company’s stock down more than 90% in pre‑market…
- Psychedelic firms Definium and Compass poised for key data releasesInvestors and analysts are focusing on two psychedelic companies as they approach pivotal milestones. Definium Therapeutics is set to release Phase 3 Voyage data for its single-dose oral LSD candi…